Fintel reports that on December 3, 2025, BMO Capital maintained coverage of Amgen (NasdaqGS:AMGN) with a Outperform ...

Amgen Inc. stock has reached a new 52-week high, hitting $345.95, marking a significant milestone for the biotechnology company. The stock is now trading just 0.99% from its 52-week high of $345.84.

William Blair starts coverage of Viridian, citing veligrotug's advantages over Tepezza and key 2026 catalysts, including FDA ...

BMO Capital analyst Evan Seigerman raised the firm’s price target on Amgen (AMGN) to $372 from $335 and keeps an Outperform rating on the shares.

Following the 2025 reconstitution, Schwab U.S. Dividend Equity ETF (SCHD) now has its largest sector exposure in Energy at 19 ...

Amgen’s stock narrative is shifting, as reflected in a slight but noticeable increase in the consensus analyst price target ...

Dragged down by losses for shares of Merck and Amgen, the Dow Jones Industrial Average is declining Monday afternoon. Supported by world-class markets data from Dow Jones and FactSet, and partnering ...

Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.

According to Benzinga Pro, Amgen Inc's peer group average for short interest as a percentage of float is 6.86%, which means ...

Shares of Regeneron Pharmaceuticals ( REGN 0.56%), a biotech giant, have been southbound over the past two years as the ...

Curious if Amgen is worth your investment dollars right now? Let’s take a clear-eyed look at where the stock stands and ...

AbbVie, Amgen, and IBM are among 2025’s top dividend performers, each up more than 30% while offering solid yields and steady ...